Legend Biotech
LEGN
159 hedge funds and large institutions have $2.6B invested in Legend Biotech in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 80 increasing their positions, 34 reducing their positions, and 17 closing their positions.
342% more call options, than puts
Call options by funds: $47.1M | Put options by funds: $10.7M
135% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 34
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
6% more funds holding
Funds holding: 150 → 159 (+9)
2.5% more ownership
Funds ownership: 17.09% → 19.59% (+2.5%)
10% less capital invested
Capital invested by funds: $2.9B → $2.6B (-$296M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$278M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$110M |
| 3 |
Janus Henderson Group
London,
|
+$83.1M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$39.9M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$38.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$56.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$55M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$48.8M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$47.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$44.8M |
LEGN Hedge Fund Activity: Q3 2022 in Review
159 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q3 2022, worth a combined $2.6B — down 10% from $2.9B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LEGN positions and 17 closed out — a net gain of 9 holders — while 80 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $278M. The largest seller was Hudson Bay Capital Management, cutting an estimated $56.9M.
- 159 institutional investors held Legend Biotech (LEGN) as of Q3 2022, up from 150 in Q2 2022.
- Funds reported $2.6B of Legend Biotech stock for Q3 2022, down 10% quarter-over-quarter.
- 26 funds opened new Legend Biotech positions in Q3 2022 and 17 closed out, a net change of +9 holders.
- The largest Legend Biotech buyer in Q3 2022 was Fidelity Investments, an estimated $278M added.
- The largest Legend Biotech seller in Q3 2022 was Hudson Bay Capital Management, an estimated $56.9M sold.
Based on aggregated 13F filings for Q3 2022.